Overview

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Status:
Recruiting
Trial end date:
2022-03-25
Target enrollment:
Participant gender:
Summary
This open-label study is being conducted to evaluate the initial safety and tolerability of IVT MHU650 in patients with DME, AMD, or RVO. The primary objective of this study is to evaluate the safety and tolerability of single ascending doses of IVT MHU650 in patients with macular edema. The secondary objective of this study is to evaluate the serum pharmacokinetic profile of total MHU650 following single IVT dose of MHU650 in macular edema patients.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals